FDA Approves Novartis’ Cushing’s Disease Drug

The FDA approved Novartis’ Isturisa (osilodrostat) for treatment of adults with Cushing’s disease who cannot undergo surgery or who still have the disease following surgery.

Cushing’s disease is a rare condition that can lead to excessive production of cortisol, a steroid hormone that controls a variety of processes in the body.

Isturisa is the first drug approved by the agency to directly address cortisol overproduction by blocking the 11-beta-hydroxylase enzyme.